CompletedInterventionalPhase 4Updated Nov 15, 2024
Drugs Brain and Behavior (DDP) | NCT04642820 | Trialant
CompletedInterventionalEarly Phase 1Updated Jan 9, 2025
Drugs Brain and Behavior (DDP)
Drugs Brain and Behavior
ClinicalTrials.gov ID
NCT04642820
Lead Sponsor
University of ChicagoOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Early Phase 1
Enrollment
138Actual
Last Update Posted
Jan 9, 2025Actual
Start Date
Nov 1, 2020Actual
Primary Completion Date
Oct 1, 2023Actual
Completion Date
Jun 1, 2024Actual
Official Title
Drugs Brain and Behavior
Brief Summary
In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
Stimulant Use
Methamphetamine
placebo oral tablet
Ages Eligible for Study
Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
BMI between 19 and 26
Right Handed
Less than 4 alcohol or caffeinated beverages a day.
Exclusion Criteria:
High blood pressure
Any medical condition requiring regular medication
Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
Individuals with a history of dependence on stimulant drugs
Women who are pregnant or trying to become pregnant.